Literature DB >> 20178775

Mode of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is oxidative stress involved?

Mariana Boiani1, Lucia Piacenza, Paola Hernández, Lucia Boiani, Hugo Cerecetto, Mercedes González, Ana Denicola.   

Abstract

Chagas disease is caused by the trypanosomatid parasite Trypanosoma cruzi and threatens millions of lives in South America. As other neglected diseases there is almost no research and development effort by the pharmaceutical industry and the treatment relies on two drugs, Nifurtimox and Benznidazole, discovered empirically more than three decades ago. Nifurtimox, a nitrofurane derivative, is believed to exert its biological activity through the bioreduction of the nitro-group to a nitro-anion radical which undergoes redox-cycling with molecular oxygen. This hypothesis is generally accepted, although arguments against it have been presented. In the present work we studied the ability of Nifurtimox and five N-oxide-containing heterocycles to induce oxidative stress in T. cruzi. N-Oxide-containing heterocycles represent a promising group of new trypanosomicidal agents and their mode of action is not completely elucidated. The results here obtained argue against the oxidative stress hypothesis almost for all the studied compounds, including Nifurtimox. A significant reduction in the level of parasitic low-molecular-weight thiols was observed after Nifurtimox treatment; however, it was not linked to the production of reactive oxidant species. Besides, redox-cycling is only observed at high Nifurtimox concentrations (>400microM), two orders of magnitude higher than the concentration required for anti-proliferative activity (5microM). Our results indicate that an increase in oxidative stress is not the main mechanism of action of Nifurtimox. Among the studied N-oxide-containing heterocycles, benzofuroxan derivatives strongly inhibited parasite dehydrogenase activity and affected mitochondrial membrane potential. The indazole derivative raised intracellular oxidants production, but it was the least effective as anti-T. cruzi. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20178775     DOI: 10.1016/j.bcp.2010.02.009

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  24 in total

Review 1.  Mitochondria and trypanosomatids: targets and drugs.

Authors:  Lianet Monzote Fidalgo; Lars Gille
Journal:  Pharm Res       Date:  2011-09-21       Impact factor: 4.200

2.  Clinical aspects of Chagas disease and implications for novel therapies.

Authors:  Cristiane Menezes; Germano Carneiro Costa; Kenneth J Gollob; Walderez O Dutra
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

3.  Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma.

Authors:  Karin Melanie Cabanillas Stanchi; Gernot Bruchelt; Rupert Handgretinger; Ursula Holzer
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

Review 4.  Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.

Authors:  Cristina Fonseca-Berzal; Vicente J Arán; José A Escario; Alicia Gómez-Barrio
Journal:  Parasitol Res       Date:  2018-09-19       Impact factor: 2.289

Review 5.  Trypanosoma cruzi antioxidant enzymes as virulence factors in Chagas disease.

Authors:  Lucía Piacenza; Gonzalo Peluffo; María Noel Alvarez; Alejandra Martínez; Rafael Radi
Journal:  Antioxid Redox Signal       Date:  2012-05-21       Impact factor: 8.401

6.  3-Hydroxykynurenine, a Tryptophan Metabolite Generated during the Infection, Is Active Against Trypanosoma cruzi.

Authors:  Carolina P Knubel; Constanza Insfran; Fernando F Martinez; Cintia Diaz Lujan; Ricardo E Fretes; Martin G Theumer; Laura Cervi; Claudia C Motran
Journal:  ACS Med Chem Lett       Date:  2017-06-12       Impact factor: 4.345

7.  Antiparasitic lethality of sulfonamidebenzamides in kinetoplastids.

Authors:  Amber Hackler; Stephen L Patrick; Elizabeth W Kahney; Daniel P Flaherty; Elizabeth R Sharlow; James C Morris; Jennifer E Golden
Journal:  Bioorg Med Chem Lett       Date:  2017-01-16       Impact factor: 2.823

8.  Trypanothione synthetase confers growth, survival advantage and resistance to anti-protozoal drugs in Trypanosoma cruzi.

Authors:  Andrea C Mesías; Natalia Sasoni; Diego G Arias; Cecilia Pérez Brandán; Oliver C F Orban; Conrad Kunick; Carlos Robello; Marcelo A Comini; Nisha J Garg; M Paola Zago
Journal:  Free Radic Biol Med       Date:  2018-10-23       Impact factor: 7.376

9.  Dibenzylideneacetones Are Potent Trypanocidal Compounds That Affect the Trypanosoma cruzi Redox System.

Authors:  Danielle Lazarin-Bidóia; Vânia Cristina Desoti; Solange Cardoso Martins; Fabianne Martins Ribeiro; Zia Ud Din; Edson Rodrigues-Filho; Tânia Ueda-Nakamura; Celso Vataru Nakamura; Sueli de Oliveira Silva
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

10.  Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites.

Authors:  Belinda S Hall; Christopher Bot; Shane R Wilkinson
Journal:  J Biol Chem       Date:  2011-02-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.